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Int J Geriatr Psychiatry. 2019;34:463–471.Objectives: Older age andmajor depressive disorder (MDD) are both risk factors for the
development of cardiovascular diseases. Testosterone has been associatedwithMDD and
metabolic syndrome (MetS) in men, although associations in women are less clear.
Therefore, we investigated whether testosterone is associated with MetS and whether
this association is different for depressed and non‐depressed older men and women.
Methods: In this prospective cohort study, 478 participants (349 patients withMDD
and 129 controls) aged between 60 and 93 years from the Netherlands Study of
Depression in Older Persons were included. Total testosterone (TT) and sex‐hormone
binding globulin levels were measured using a second‐generation radioimmune assay.
Free testosterone (FT) was calculated based on TT. MetS was defined according to
the National Cholesterol Education Program Adult Treatment Panel III criteria.
Results: A higher risk for MetS was found in men with low FT and TT (odds ratio
[OR]: 0.67, 95% confidence interval [95%CI]: 0.47‐0.95 and OR: 0.51, 95%CI: 0.34‐
0.75), and in women with high FT (OR: 1.41, 95%CI: 1.08‐1.82). Strong associations
in the same direction were found with adiposity, glucose, and plasma lipid MetS com-
ponents at baseline, but not with changes in these components at 2‐year follow‐up.
The associations did not significantly differ between MDD patients and controls.
Conclusions: Independently of having MDD, low testosterone levels in men and, in
contrast, high testosterone levels in women were significantly associated with MetS
and its components.
KEYWORDS
depressive disorder, major, metabolic syndrome, older adults, testosterone1 | INTRODUCTION
The older population shows the highest prevalence of the metabolic syn-
drome (MetS)1 which puts this group at increased risk for cardiovascular
diseases (CVD) and cardiovascular‐relatedmortality.2 Among the proposed- - - - - - - - - - - - - - - - - - - - - - - - - - -
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tric Psychiatry Published by John Wmechanisms to explain the association between age and MetS is the influ-
ence of testosterone. Testosterone levels decline during aging, especially in
men, who have 10 times higher levels than women in younger adulthood.3
Low testosterone levels in men and high levels in women are
thought to alter adipose tissue function, with effects on lipid- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Key points
• Low free and total testosterone levels in men and in
contrast high free testosterone levels in women are
associated with the metabolic syndrome and its
components in older adults.
• Depression does not alter the association between
testosterone and metabolic syndrome.
464 DE WIT ET AL.metabolism, insulin resistance, and fat mass expansion which may
induce metabolic disadvantages.4 However, this association is com-
plex, as testosterone levels have both detrimental and beneficial
effects depending on the type of tissue and sex.4 Earlier research in
men has shown that low testosterone levels may contribute to the
development of MetS but that the magnitude of this effect is depen-
dent on several other factors and that the relation may also be bidirec-
tional.5,6 In contrast to the findings in men, higher testosterone levels
in women have been associated with MetS.7 That said, prospective
analyses are lacking and not all studies have found this association.8
In spite of a range of studies on this issue, many aspects of the
complex relationship between testosterone and MetS remain unclear.
This warrants further investigation into possible underlying patho-
physiological processes, especially in the older population who are at
the highest CVD mortality risk.9 Influencing factors may include major
depressive disorder (MDD), which has been associated with 80% to
90% elevated risk for CVD onset.10 Additionally, the presence of MetS
in depressed older adults has been associated with greater symptom
severity of depression.11 Dysregulations in the immune response and
the hypothalamic‐pituitary‐adrenal axis seen in MDD12 closely
respond to alterations in the hypothalamic‐pituitary‐gonadal axis. This
not only alters testosterone levels but also impacts its function.4,13,14
Indeed, low testosterone levels have been associated with MDD in
men,15-18 although associations in women are inconsistent.8,17,19,20
Given these associations, we hypothesized that MDD or the use
of antidepressants increases the vulnerability for testosterone level
alterations. Therefore, we aimed to determine the associations
between testosterone and MetS in older adults and test whether this
association is stronger in depressed or antidepressant‐using patients.2 | MATERIALS AND METHODS
2.1 | Study population
Data for this study were obtained from Netherlands Study of Depres-
sion in Older Persons (NESDO). For methodological details, we refer
to previously published work.21,22 In short, this multicentre prospec-
tive cohort aims to study the course, predictors, and consequences
of late‐life depression. In total, 510 participants, aged 60 to 93 years,
were recruited from 2007 to 2010. A group of 378 older persons with
MDD, dysthymia, or minor depression was recruited from both
general practitioners and mental health care facilities to cover a wide
range of severities. The 132 controls without a history of depression
were recruited via general practitioners. After baseline assessment,
participants were invited for a second face‐to‐face interview with
repeated measures of psychological, social, and physical functioning
after 2 years.23 During this period, 28 people died. Of the 482 partic-
ipants who were still available for the study, 401 (83.4%) took part in
the follow‐up assessment. All participants gave their written and oral
consent. The study protocol was approved by the Ethical Review
Board of the VU Medical Center in Amsterdam, and subsequently by
the local ethical review boards.
The presence or absence of depression was assessed by the
Composite Interview Diagnostic Instrument24 at baseline and after2 years of follow‐up and was administered in face‐to‐face interviews.
Depression diagnosis was present when participants met the criteria
with a 6‐month recency.
For the current study, we analysed MDD patients (N = 359) and
healthy controls (N = 132). Thirteen participants were excluded due
to missing data on plasma testosterone or sex‐hormone binding glob-
ulin (SHBG). In total, 349 MDD patients (119 men and 230 women)
and 129 controls (50 men and 79 women) were available for the base-
line analyses. Ninety‐nine participants (36 men and 63 women)
dropped out between the baseline and the 2‐year follow‐up assess-
ment (20.7% of baseline sample). Female non‐responders suffered
more often from MDD, and male non‐responders were older com-
pared with responders. MetS rates did not differ between responders
and non‐responders. In total, 266 MDD patients (91 men and 175
women) and 113 control participants (42 men and 71 women) were
available for longitudinal analysis.2.2 | Measurements
Predictors included testosterone (TT), free testosterone (FT), and
SHBG. Blood was taken after an overnight fast at baseline (mean time
of sampling 9:04 AM; range 8:10 to 10:45). EDTA plasma was stored
at −80°C until determination of the androgenic markers. TT was mea-
sured using a second‐generation testosterone assay without extrac-
tion (Architect i2000 analyzer; Abbott Diagnostics, Abbott Park, IL).
In contrast to earlier radioimmune assays, second‐generation testos-
terone assays suffer less from cross‐reactivity with other steroid hor-
mones and are less influenced by SHBG levels.25,26 Strong correlation
coefficients are reported between our radioimmunoassay and the gold
standard ID‐LC‐MS/MS measurement in women (R = 0.95).26 Intra‐
and inter‐assay variations were between 4% and 10% at concentra-
tions of 0.02, 2, and 20 nmol/L. The lower limit of quantification
was 0.45 nmol/L. In 23 of 318 women (7.2%), the TT level was below
the threshold and therefore imputed as 0.44 nmol/L as done before.19
SHBG was measured using an automated immunometric assay
(Architect i2000 analyzer). Intra‐ and inter‐assay variations were
between 4% and 6% over the whole range. The lower limit of detec-
tion for SHBG was 2 nmol/L. FT was calculated from TT, SHBG, and
albumin levels using the formula published by Vermeulen.27
Outcome measures were MetS (as a dichotomous variable) and its
individual components (as continuous variables) at baseline and after
2 years of follow‐up. MetS was defined according to the adjusted
National Cholesterol Education Program Adult Treatment Panel III
DE WIT ET AL. 465(ATP III) criteria.2 To fulfil the diagnosis of MetS, at least three of the
following criteria had to be met: blood pressure >130 mmHg systolic
or >85 mmHg diastolic or antihypertensive medication; waist circum-
ference >102 cm for men and >88 cm for women; fasting glucose levels
>5.6 mmol/L (100 mg/dL) or anti‐diabetic medication; high‐density‐
lipoprotein (HDL) cholesterol levels <1.0 mmol/L (40 mg/dL) for men
and <1.3 mmol/L (50 mg/dL) for women or medication for reduced
HDL cholesterol; and fasting triglycerides levels >1.7 mmol/L
(150 mg/dL) or medication for hypertriglyceridemia.
Waist circumference was determined by measuring tape, measur-
ing between the lower rib margin and the iliac crest following normal
expiration, over light clothing. HDL cholesterol, triglycerides, and glu-
cose levels were measured by standard laboratory methods after over-
night fasting. Nineteen patients were set as missing value because
they did not fast before the assessment. Blood pressure was measured
in a supine position on the right arm by an electronic Omron sphygmo-
manometer and was averaged over two readings. HDL cholesterol
levels, triglyceride levels, and fasting glucose levels were adjusted for
medication effects.28-30 When participants were using antihyperten-
sive medication, 10 mmHg was added to the systolic blood pressure
and 5 mmHg was added to the diastolic blood pressure.31 When
participants were using fibrates, 0.10 mmol/L [3.8 mg/dL] was
subtracted from HDL cholesterol and 0.67 mmol/L [60 mg/dL] was
added to triglycerides.28,29 When participants were using anti‐diabetic
medication, when the glucose level was below 7 mmol/L [126 mg/dlL],
a value of 7 mmol/L was given.30 Body mass index (BMI) is not a MetS
component but is often used as a weight measurement. Therefore, we
included this variable as an outcome measure as well, to see whether
both assessments are comparable. In general, waist circumference
and BMI are highly correlated, independent of sex (r = 0.93, range
0.87‐0.95).322.3 | Statistical analyses
All analyses were performed in strata separately for men and women.
Data were analysed using IBM SPSS Statistics 24. A two‐tailed P value
<0.05 was considered statistically significant.
Characteristics were determined at baseline, using percentages,
by chi‐squared tests or means with SD by analysis of variance,
dependent on the type of variable.
The first aim was to test the association between TT and FT with
MetS diagnosis (dichotomous) and its individual components (continu-
ous) at baseline and after 2‐year follow‐up. In the cross‐sectional
analyses, these associations were examined using logistic and linear
multivariable regression analyses, when appropriate. All analyses were
adjusted for age and for education, smoking status, alcohol use,
number of chronic diseases, and testosterone‐affecting medication in
a second adjustment. Level of education was specified in years of
education. Smoking status was dichotomized into non‐ and current
smoker. Alcohol use was defined as daily alcohol intake in units. The
number of chronic diseases was counted (including hypertension,
range 0 through 8). Use of medication was considered as present
when using Anatomical Therapeutic Chemical Classification (ATC)
codes at least 50% of the days.33 Out of the 478 participants, 33 weretaking medications that could influence their testosterone level; seven
participants were taking sex hormones (ATC code G03), six partici-
pants were taking selective estrogen receptor modifiers (SERM) or
aromatase inhibitors (ATC code L02B), and 21 participants were taking
glucocorticoids (ATC code H02AB). All users of sex hormones,
SERM's, or aromatase inhibitors were female. As none of them was
using (anti‐) androgens and their testosterone levels were within the
reference intervals, we decided not to exclude these women. How-
ever, the main analyses were repeated in a sensitivity analysis with
exclusion of this group. Nonlinear associations were analysed by
adding squared TT and FT, respectively, to the model. FT was logarith-
mically transformed to reduce their positively skewed distributions.
For interpretation purposes only, TT and FT were standardized (calcu-
lated z‐scores) before entering the regression model calculating odds
ratios (ORs) for MetS. In the prospective analyses, associations
between standardized TT and FT with the change in MetS compo-
nents over 2 years were examined using linear regression analyses.
Two‐year follow‐up values of MetS components were subtracted
from baseline values. Therefore, a positive delta score means a lower-
ing of MetS components over 2 years. For waist circumference,
triglycerides, blood pressure, glucose, and BMI, this would, in most
cases, be associated with an improved metabolic profile. In contrast,
a positive delta score for HDL would in most cases mean a worse met-
abolic profile. These delta scores were entered as outcomes in the
regression model. Again, all analyses were adjusted for age first and
adjusted for the other covariates afterwards as mentioned before.
To test whether the association between testosterone levels and
MetS was similar for persons with and without MDD, interaction
terms (ie, testosterone * MDD) were entered in the cross‐sectional
models. Next, the interaction term testosterone*antidepressant use
was added to the regression models. When interactions were
significant (P < .05), tests were run separately for MDD subgroups.
All analyses were adjusted according to the previously mentioned
models.3 | RESULTS
3.1 | Findings in older men
The characteristics of the 169 men are shown in Table 1. Of our sam-
ple of men, 70% was currently depressed, and 46% was diagnosed
with MetS. The mean plasma TT and FT levels were 16.7 ± (SD)
6.3 nmol/L and 307.1 ± 100.0 pmol/L.3.1.1 | Cross‐sectional associations between testos-
terone and MetS
Associations betweenTT and FT with MetS (components) and BMI are
shown in Table 2 and Figures 1 and 2. Overall, both low TT and FT
levels were associated with a higher risk for MetS (standardized OR:
0.51 CI95%; 0.34; 0.75 and OR: 0.67 CI95%; 0.47; 0.95). Low andro-
gen levels were linearly associated with adverse MetS components
except for blood pressure, with the strongest associations displayed
for TT levels. After adjustment for all covariates, a 1SD (ie, 6.3 nmol/
TABLE 1 Baseline socio‐demographic, lifestyle, and clinical charac-





Age (years) 69.6 ± 7.4 70.9 ± 7.3
Northern European ancestry 94.1% 94.5%
Education (years) 11.9 ± 3.8 10.5 ± 3.2
BMI (kg/m2) 26.5 ± 3.7 26.4 ± 4.5
Smoking 19.5% 23.2%
Alcohol use (no. drinks/day) 0.9 ± 1.2 0.6 ± .8
Chronic disease 2.1 ± 1.5 2.5 ± 1.6
Testosterone affecting medication 4.1% 6.5%
Androgenic features
Testosterone (nmol/L) 16.7 ± 6.3 0.96 ± 0.40





Waist circumference (cm) 99.6 ± 11.4 91.8 ± 12.8
Triglyceridesa (mmol/L) 1.5 ± 0.8 1.4 ± 0.7
HDL cholesterolb (mmol/L) 1.3 ± 0.3 1.7 ± 0.4
Systolic blood pressure (mmHg) 155.8 ± 20.8 151.3 ± 22.4
Diastolic blood pressure (mmHg) 86.3 ± 10.9 82.8 ± 11.3
Fasting glucosec (mmol/L) 6.1 ± 1.3 5.8 ± 1.3
Interactions
Diagnosis of major depressive disorder 70.4% 74.4%
Use of antidepressants 49.7% 55.0%
Data are percentages or mean ± standard deviation (SD). P‐values are
based on chi‐squared tests (for dichotomous and categorical variables) or
t‐tests for independent samples (for continuous variables). Triglyceride,
HDL cholesterol, blood pressure, and fasting glucose values were adjusted
for medication use (see measurements).
aTo convert the values of triglycerides to milligrams per decilitre, divide by
0.01129.
bTo convert the values for HDL cholesterol to milligrams per decilitre,
divide by 0.02586.
cTo convert the values of glucose to milligrams per decilitre, divide by
0.05551.
466 DE WIT ET AL.L) lower TT level was associated with a mean 3.5 cm higher waist
circumference (P < .001), a mean 0.18 mmol/L higher triglycerides
(P = .006), a mean 0.04 mmol/L lower HDL (P = .01), a mean
0.23 mmol/L higher fasting glucose (P = .03), and a mean 0.96 kg/m2
higher BMI (P < .001). SHBG showed ORs and standardized betas in
same direction as for TT and FT (data not shown).3.1.2 | Longitudinal associations between testoster-
one and MetS
Associations betweenTT and FT with 2‐year changes in MetS compo-
nents and BMI are shown in Table 3. In contrast to the cross‐sectional
analyses, neither baseline TT nor FT levels were associated with
changes in MetS components over 2 years, except for fasting glucose.
A higher FT level was associated with lower fasting glucose levels
after 2 years (P = .02).3.1.3 | Moderating effects of MDD
Although associations were slightly stronger in the MDD group than in
controls (Figure 1), they were not statistically significantly different.
For the MetS components, there was only one exception. The adverse
effects of lower TT levels on systolic blood pressure were stronger in
depressed patients compared with controls (standardized β for inter-
action −0.46 (P = .04), for MDD patients −0.20 (P = .02) and for con-
trols 0.14 (P = .43).3.2 | Findings in older women
The characteristics of the 309 women are shown in Table 1. Of
our female sample, 72% was currently depressed, and 43% was
diagnosed with MetS. The mean plasma TT and FT levels were
0.96 nmol/L ± 0.40 nmol/L and 14.1 pmol/L ± 7.62 pmol/L
(mean ± SD).3.2.1 | Associations between testosterone and MetS
Association between TT and FT with MetS (components) and BMI are
shown in Table 2 and Figures 1 and 2. Overall, high FT levels were
associated with a higher risk for MetS (standardized OR: 1.41;
95%CI: 1.08‐1.82; P = .01). After adjustment for all covariates, high
FT, but not TT, levels were linearly associated with MetS as well as
adverse MetS components, except for systolic and diastolic blood
pressure. In contrast to men, a 1‐SD (7.62 pmol/L) higher FT level
was associated with a mean 2.4 cm higher waist circumference
(P < .001), a mean 0.18 mmol/L higher triglycerides (P < .001), a mean
0.05 mmol/L higher HDL (P = .02), a mean 0.18 mmol/L higher fasting
glucose (P = .02), and a mean 1.0 kg/m2 higher BMI (P < .001). SHBG
showed standardized betas in opposite direction as for FT. The exclu-
sion of 13 women using aromatase inhibitors, SERM, estrogens, or
progestagens did not remarkably change the results (standardized
OR: 1.40; 95%CI: 1.07‐1.82; P = .01).3.2.2 | Longitudinal associations between testoster-
one and MetS
Associations betweenTT and FT with a 2‐year change in MetS compo-
nents and BMI are shown in Table 3. As in men, neither TT nor FT
were associated with changes in MetS components over 2 years.3.2.3 | Moderating effects of MDD
Similar to older men, associations were slightly stronger in the MDD
group than in controls (Figure 1), although not statistically significantly
different. Only women with MDD and high levels of FT showed a
higher mean waist circumference and BMI compared with controls
(standardized β for interaction 1.13 [P = .03] and 1.05 [P = .045]),
for MDD participants 0.24 (P < .001) and 0.29 (P < .001) and for
controls −.04 (P = .77) and.02 (P = .88).
TABLE 2 Associations of TT and FT levels with MetS diagnosis and components in 169 men and 309 women
MetS diagnosis Waist Triglycerides HDL Systolic BP Diastolic BP Glucose BMI
OR (95%CI) p β p β p β p β p β p β p β p
Men
Testosterone
Age adjusted 0.52 (0.36–0.76) <.001 −0.34 <.001 −0.21 .005 0.23 .002 −0.13 .08 −0.09 .22 −0.18 .02 −0.29 <.001
Fully adjusteda 0.51 (0.34–0.75) <.001 −0.33 <.001 −0.22 .006 0.19 .01 −0.11 .13 −0.09 .22 −0.18 .03 −0.26 <.001
Free testosterone
Age adjusted 0.66 (0.46–0.92) .02 −0.31 <.001 −0.15 .06 0.12 .13 −0.03 .67 −0.04 .65 −0.16 .05 −0.29 <.001
Fully adjusteda 0.67 (0.47–0.95) .02 −0.30 <.001 −0.15 .06 0.09 .21 −0.02 .79 −0.04 .58 −0.14 .09 −0.27 <.001
Women
Testosterone
Age adjusted 0.89 (0.70–1.12) .33 −0.03 .66 0.02 .67 0.06 .34 0.07 .23 0.08 .18 −0.02 .77 0.02 .69
Fully adjustedc 0.92 (0.71–1.19) .53 −0.01 .92 0.02 .69 0.08 .19 0.08 .19 0.10 .08 −0.01 .86 0.06 .28
Free testosterone
Age adjusted 1.31 (1.04–1.66) .02 0.19 .002 0.25 <.001 −0.12 .04 0.09 .11 0.09 .11 0.16 .01 0.22 <.001
Fully adjusteda 1.41 (1.08–1.82) .01 0.19 .001 0.25 <.001 −0.13 .02 0.11 .07 0.10 .08 0.14 .02 0.23 <.001
Data are standardized odds ratios (OR) with 95% CI or standardized betas determined by (log) linear regression. As the independent variables were naturally
log‐transformed in the logistic regression analyses, a one‐unit change in FT or TT will not be a constant effect in the odds but will vary with FT and TT itself.
The dependent and independent variables were therefore standardized, in order for the effect sizes of the ORs to become comparable among the different
models. The standardized ORs and beta coefficients refer to how many SD the dependent variable will change per SD increase in the independent variable.
aAdjusted for age, education, smoking status, alcohol use, number of chronic diseases, and testosterone affecting medication.
Abbreviation: BP, blood pressure.
FIGURE 1 Relationship between plasma total and free testosterone and metabolic syndrome in 169 men and 309 women. Adjusted odds ratios
for metabolic syndrome are shown for all participants and separately for depressed and controls on a logarithmic scale. Interaction terms for free
testosterone and total testosterone with major depressive disorder are shown as well, but were not significant. Total testosterone and free
testosterone levels were standardized before analysis. The size of the diamonds is proportional to the number of participants. Error bars represent
standard errors (SE)
DE WIT ET AL. 4674 | DISCUSSION
In this study, we aimed to investigate whether plasma testosterone is
associated with MetS and whether this association is different for
depressed and non‐depressed older men and women. Strong associa-
tions between lower levels of TT and FT in men and, in contrast,
higher levels of FT in women with MetS and its components werefound. However, the association in depressed older people did not
differ significantly from healthy controls.
Our findings in men of an inverse association between testoster-
one and MetS are in line with earlier findings in men aged older than
608,34,35 as were the relationships with MetS components in one
study,35 but not in the other study.8 In contrast, relationships of
largely the opposite direction were found in our sample of older
FIGURE 2 Relationship between plasma free testosterone and metabolic syndrome components in 169 men and 309 women. Free testosterone
levels were categorized for visualization purposes only, as all analyses were carried out with continuous data. Free testosterone levels were
loge‐transformed before analysis, and back‐transformed geometric mean levels are presented on logarithmic scales. Error bars represent standard
errors (SE). The sizes of the boxes are proportional to the number of participants
TABLE 3 Associations of TT and FT levels with delta changes in MetS components in 133 men and 246 women over 2 years
ΔWaist ΔTriglycerides ΔHDL ΔSystolic BP ΔDiastolic BP ΔGlucose ΔBMI
β p β p β p β β β p β p β p
Men
Testosterone
Age adjusted −0.09 .31 0.06 .53 0.03 .76 0.06 .53 0.00 .99 0.15 .11 −0.08 .36
Fully adjusteda −0.10 .26 0.07 .47 −0.01 .90 0.05 .63 0.01 .94 0.15 .10 −0.12 .20
Free testosterone
Age adjusted −0.05 .57 0.12 .21 −0.03 .74 0.07 .46 0.04 .70 0.22 .02 −0.09 .30
Fully adjusteda −0.07 .48 0.13 .17 −0.06 .49 0.07 .44 0.05 .62 0.22 .02 −0.14 .14
Women
Testosterone
Age adjusted −0.05 .50 0.01 .86 0.11 .14 −0.05 .43 −0.00 .97 −0.01 .84 −0.03 .61
Fully adjusted a −0.05 .47 0.02 .81 0.10 .14 −0.05 .47 0.00 .99 −0.02 .81 −0.03 .70
Free testosterone
Age adjusted 0.01 .84 0.12 .09 0.07 .36 −0.03 .72 0.05 .61 0.00 .96 −0.06 .35
Fully adjusted a −0.02 .76 0.12 .10 0.05 .48 −0.03 .68 0.04 .61 −0.01 .88 −0.05 .48
Data are standardized betas determined by linear regression. As the independent variables were naturally log‐transformed in the logistic regression anal-
yses, a one‐unit change in FT or TT will not be a constant effect in the odds but will vary with FT and TT itself. The dependent and independent variables
were therefore standardized, in order for the effect sizes of the beta's to become comparable among the different models. The standardized beta
coefficients refer to how many SD the dependent variable will change per SD increase in the independent variable.
aAdjusted for age, education, smoking status, alcohol use, number of chronic diseases, and testosterone affecting medication.
Abbreviation: BP, blood pressure.
468 DE WIT ET AL.women. Higher levels of FT (but not of TT) were associated with MetS
and its components, which is also in line with previous studies of
postmenopausal women.7,36-38 Similarly, in younger women with poly-
cystic ovarian syndrome (PCOS), high FT and TT levels have also been
linked to MetS,13 whereas such data are largely lacking in postmeno-
pausal women with PCOS.13 Caution should be taken wheninterpreting findings with calculated FT in epidemiological research,
as the formula is importantly dependent on age.39
Sex‐hormone binding globulin may explain why women, in con-
trast to men, are particularly sensitive to FT and not to TT levels. In
our study, the associations for SHBG with MetS were in the same
direction for both sexes, which is remarkable given the contrasting
DE WIT ET AL. 469results for FT and TT. SHBG binds to androgens and determines for a
large part the amount of FT. However, it also has metabolic effects
and helps to protect women against exposure to excessively high
testosterone levels. The occupancy of SHBG steroid‐binding sites by
androgens is sex dependent with an occupation rate of only 18% in
women and up to 56% in men. This possibly leads to a more swift
response to increased or decreased androgen levels in women,40
which might explain our strong findings with FT but not with TT.
In line with other studies, we found no longitudinal associations
between TT and FT and the incidence of MetS in older people.41-43
Any changes in (components of) the MetS may have already taken
place years before our baseline assessment, as a high or low
androgen status may have been present since puberty—exerting its
metabolic effects over decades. Moreover, a single measurement of
testosterone could have been insufficient to detect associations.
However, as suggested before,43 the case of reverse causation might
be true as well supposing TT and FT can be considered as a marker of
MetS, but any potential causal role should be investigated during
longer follow‐up periods and/or in experimental designs. In supple-
mentation studies, testosterone may help to improve lipid profiles,
body composition, and insulin sensitivity in older and hypogonadal
men, whereas anti‐androgenic treatment had similar effects in
women with PCOS.4 Unfortunately, experimental studies in older
women are scarce.44
Despite being the subject of many studies, the underlying mech-
anisms of the relationship between MDD and MetS remain largely
unclear. Several mechanisms, like unhealthy lifestyle habits and
immune‐inflammatory dysregulation, may be involved, which all influ-
ence androgen levels.4,13 We could not confirm, however, that the
relationship between androgenic markers and MetS is moderated
by MDD or antidepressant use in older people, since associations
were similar in depressed and non‐depressed older people. Given
the complexity of the relationship between androgenic markers and
MetS and the heterogeneity of MDD, it is possible that the interac-
tion terms that were tested were too crude to be informative.
Regarding antidepressants, effects on immune‐inflammatory dysregu-
lation but also obesity might be medication‐type specific.45
Moreover, certain subtypes of MDD might be more vulnerable for
testosterone alterations. In addition, the hypothalamic‐pituitary‐
adrenal axis and hypothalamic‐pituitary‐gonadal axis are closely
linked, as the end‐products steroid hormones of both systems have
the same backbone, being derived from cholesterol. Furthermore,
these two systems crosstalk, with stimulating and inhibiting effects
from both sides.46
Some limitations of our study need to be discussed. TT was
measured at one time point, which limits its merit to reflect the
androgenic status of the participants. However, TT gradually declines
with age and may be too small to be measurable and of clinical
importance over a period of 2 years for both men and women.43,47
Previous studies generally also measured the androgenic status at
one time point. In addition, a radioimmune assay was used to deter-
mine testosterone levels, which is less reliable than liquid chroma-
tography with tandem mass spectrometry (LC‐MS/MS) analyses, in
particular at the lower concentrations generally measured in women
(<5 nmol/L).48,49 However, as stated in the method section, goodcorrelations have been reported between this radioimmunoassay
we used and the ID‐LC‐MS/MS measurement of testosterone.26 A
strength of our study is its design with measurements of MetS com-
ponents at two time points, which enabled us to study testosterone
not only as a marker but also as a predictor for changes in
MetS components. Finally, we studied the association in a well‐
characterized sample of older subjects with standardized assessment
of psychiatric disorders.
In conclusion, our study showed that lower TT and FT levels in
older men and higher levels of FT in older women were associated
with MetS. Remarkably, testosterone had opposite adverse effects
on the metabolic phenotype among the sexes. However, this associa-
tion was not moderated by MDD or antidepressant use. Therefore, TT
and FT could not explain the previously reported relationship between
MDD and MetS in older people.
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